


Why is it important to optimise your patients' COPD treatment from the start?



*Annual rate of decline in FEV₁ in COPD patients based on GOLD classification of disease severity¹

Decline in lung function at GOLD 2¹ leads to decline in patient activity² and spirals in to disengagement³



Even in early COPD, breathlessness impacts patients' daily lives, making even routine tasks a challenge⁴

Are you aware of how your patient's COPD is **affecting their everyday lives?**



Is monotherapy enough?

The **majority** of COPD patients receiving monotherapy treatment are **still symptomatic** and are experiencing mild to moderate dyspnoea¹¹




SPIOLTO® RESPIMAT®:
Built on the strong roots of SPIRIVA® enhanced by fast onset olodaterol

SPIOLTO® RESPIMAT® provides significant improvements over SPIRIVA® that patients feel from the start of maintenance therapy⁵⁻¹⁰



Click on each section to learn more

How can **SPIOLTO® RESPIMAT®** help COPD patients from the start of maintenance therapy?



Improvement in lung function beyond SPIRIVA® in GOLD 2 patients⁵



43%

Improvement in breathlessness beyond SPIRIVA® for **GOLD 2** patients¹²

C	D
A	B

Quality of life benefits beyond SPIRIVA® are most pronounced in **GOLD B** patients¹³

Prescribing information

This information is from an international website which is intended for healthcare professionals not located in the United States of America (US) and the United Kingdom (UK). SPIOLTO® RESPIMAT® is subject to country-specific regulations and the approved product label may vary from country to country. Information on this website is derived from the approved European Summary of Product Characteristics. Please refer to your local product label for full details.

References;
 1. Tantucci C, et al. Int J Chron Obstruct Pulmon Dis. 2012;7:95-9. | 2. Watz H, et al. Eur Respir J. 2009;33:262-72. | 3. Reardon J. Am J Med. 2006;119:32-4. | 4. O'Donnell DE, et al. PLoS ONE. 2014;9:e96574. | 5. Ferguson GT, et al. Adv Ther. 2015;32:523-36 and supplementary information. | 6. SPIOLTO® RESPIMAT® Summary of Product Characteristics. | 7. Beeh KM, et al. Pulm Pharmacol Ther. 2015;32:53-9. | 8. Singh D, et al. Poster presented at the 25th Annual Congress of the European Respiratory Society, Amsterdam, Netherlands, September 26-30, 2015: Poster PA2958. | 9. Buhl R, et al. Eur Respir J. 2015;45:969-79. | 10. SPIRIVA® RESPIMAT® Summary of Product Characteristics. | 11. Dransfield MT, et al. Prim Care Respir J. 2011;20(1):46-53. | 12. Singh D, et al. Respir Med. 2015;109(suppl 1):S7-S8. | 13. Singh D, et al. Respir Res. 2016;17:73.

